ArticleJournal of molecular histology2025
Upregulation of circRNA_0002286 protects against brain ischemia/reperfusion injury after remote ischemic postconditioning via microRNA-124-3p/VLCAD axis.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Remote ischemic postconditioning (RIPostC) has been reported to have a brain-protection effect on ischemic stroke. In the previous studies, we found that the circRNA_0002286/ miR-124-3p/very long-chain acyl-CoA dehydrogenase (VLCAD) pathway may play a regulatory role in ischemic stroke injury. However, the regulatory mechanism of the pathway remains unknown. In this study, different reperfusion times were respectively set to screen the optimal treatment time of oxygen–glucose deprivation/reoxygenation (OGD/R), then primary neurons and PC12 cells were induced by OGD/R. The RIPostC rat model was established by repeatedly clamping the femoral artery after transient middle cerebral artery occlusion. Reverse transcription real-time polymerase chain reaction was performed to detect the expression of circRNA_0002286, miR-124-3p, and VLCAD mRNA. Western blot was used to detect VLCAD protein. The fluorescence intensity of NeuN was detected using immunofluorescence staining. Dihydroethidium staining was performed to observe cell hypoxia. The targeting relationship among miR-124-3p, circRNA_0002286, and VLCAD was verified by dual-luciferase reporter assay. Fluorescence in situ hybridization assay was used to detect the localization of circRNA_0002286 and miR-124-3p in PC12 cells. Cell viability was measured using cell counting kit-8. Cell apoptosis was evaluated using Annexin V/FITC/PI double staining. 2,3,5-triphenyl tetrazolium chloride, hematoxylin–eosin, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining were used to observe the pathological damage of brain tissue in rats. Results found that circRNA_0002286 and VLCAD mRNA decreased in OGR/R-induced neurons, PC12 cells, and RIPostC rats. Knockdown of circRNA_0002286, overexpression of miR-124-3p, or knockdown of VLCAD inhibited the proliferation and induced apoptosis of PC12 cells, promoted brain damage in rats. Overexpression of circRNA_0002286, miR-124-3p inhibition, or overexpression of VLCAS promoted brain protection of RIPostC rats. Mechanistically, overexpression of circRNA_0002286 promoted VLCAD level through sponging miR-124-3p and enhanced the neuroprotective effect of RIPostC. In conclusion, circRNA_0002286/miR-124-3p/VLCAD regulatory network may be a prospective therapeutic target for ischemic stroke.
Indexed as
Identifiers
40615768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.